Investegate announcements from Immunicum AB, Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress Ongoing ADVANCE II study evaluating DCP-001 in AML patients is nearing target enrollment of 20 patients Immunicum AB (publ; IMMU.ST) today presents clinical data showing DCP-001’s ability to induce immune responses to a broad range of tumor associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-0